NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Guangzhou Jeep Biotechnology JEEP

Published 12 Nov 2026. 37-page investigative report on who is behind Guangzhou Jeep Biotechnology JEEP: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 61 Finnrick lab tests, JEEP's overall pass rate is 80% (49 pass / 10 fail). The result is product-specific rather than a vendor-wide green light: Tirzepatide and GHK-Cu are the stronger signals, Retatrutide has depth but failures, and CJC-1295 sits at the weak end. Ratings also move under stricter fill and purity grading, so the full appendix matters.

The cleanest buying path in the record is the GLP-1 Forum sponsor thread to jeepbiotechx.com. That useful anchor sits inside a high-confusion web footprint: a separate JEEP Biotech site makes a conflicting only-official claim while carrying near-clone manufacturer text and an impossible online-history counter, and a Name.com/NS1 lookalike cohort routes buyers toward a capital-I Telegram spoof of Molly.

The public accountability chain remains thin. Terms and legal pages provide trade names and Gmail contacts, but no verified legal entity, USCC, registered office, importer, U.S. distributor filing or beneficial owner was established in the sources reviewed. Public materials also show sales personas posting COAs, not a named quality manager or independent release authority; that is a disclosure gap, not proof that technical oversight is absent.

The highest-severity product issue is narrower and sharper: prior Tirzepatide 30 mg orange-cap inventory tied to JP20250616 had repeated endotoxin failures and awkward batch traceability. Later endotoxin posting is favorable, but current buyers still need exact-lot, lab-hosted evidence rather than generic purity reassurance.

Inside the full report:

  • Appendix A per-product Finnrick pass/fail rates and methodology-divergence charts for all 6 tested products
  • Dated forum and storefront authentication record for jeepbiotechx.com, including WhatsApp and Telegram handle changes
  • RDAP/domain register for 18 JEEP-related domains, with the Name.com/NS1 lookalike cluster mapped
  • Template and infrastructure evidence linking jeepbiotech.com, nanjingpeptide.com, AluraBio and Peptide Mom surfaces
  • Tirzepatide 30 mg orange-cap endotoxin and batch-traceability case file
  • Buyer guidance on COA verification, crypto-payment exposure, warehouse routing and do-not-use channels

Risk assessment

  • Copycat / brand-confusion risk — high: jeepbiotechx.com is sponsor-authenticated, but contested jeepbiotech.com, NS1 lookalikes, @moIlyjeep0, suppressed guangzhoujeepbiotechnology.com / jeeppeptides.net and buyer-loss reports make wrong-channel exposure high.
  • No identifiable legal counterparty / ownership-accountability risk — high: Jeep Peptides USA and Guangzhou JEEP surfaces provide no USCC, registration number, registered office, officer, importer or UBO.
  • Tirzepatide 30 mg endotoxin / traceability risk — high: Tirzepatide 30 mg orange-cap / JP20250616-related materials reported 1,350 / 1,360 / 2,306 EU/vial endotoxin; current T30 requires exact-lot endotoxin proof despite Tirzepatide’s stronger Finnrick rating.
  • Weak product-specific quality risk — high: Tesamorelin is 48.7% on 4 tests with 2 failures and CJC-1295 is 35.23% on 3 tests; those products should not borrow confidence from stronger GHK-Cu, Tirzepatide or Retatrutide results.
  • COA and batch-document-control risk — medium: Janoshik/Freedom guarantee language is inconsistent, Janoshik verification was CAPTCHA-gated, the batch verifier is not endotoxin/traceability proof, and a contested jeepbiotech.com COA was image-only with Photoshop metadata.
  • Payment and logistics-continuity risk — medium: Sponsor-channel sales are crypto-only; China warehouse saw September and November suspensions and destination exclusions, while the U.S. warehouse is narrower.